Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway

Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway

10.3390/cancers13215479

Saved in:
Bibliographic Details
Main Authors: Arora, Loukik, Mohan, Chakrabhavi Dhananjaya, Yang, Min Hee, Rangappa, Shobith, Deivasigamani, Amudha, Kumar, Alan Prem, Kunnumakkara, Ajaikumar B., Garg, Manoj, Chinnathambi, Arunachalam, Alharbi, Sulaiman Ali, Alahmadi, Tahani Awad, Rangappa, Kanchugarakoppal S., Hui, Kam Man, Sethi, Gautam, Ahn, Kwang Seok
Other Authors: PHARMACOLOGY
Format: Article
Published: MDPI 2022
Subjects:
Orthotopic
SHP2
STAT3 signaling inhibitor
Tris DBA
Xenograft
Online Access:https://scholarbank.nus.edu.sg/handle/10635/232792
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Internet

https://scholarbank.nus.edu.sg/handle/10635/232792

Similar Items